Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized, double-blind, placebo-controlled trial of JNJ-77242113 in moderate to severe plaque psoriasis with randomized withdrawal and retreatment
2023-505120-59-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2023
- Modality
- Peptides
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing JNJ-77242113 with Placebo (2 arms). Primary endpoints: IGA 0/1 with ≥2-grade improvement at Week 16 and PASI 90 at Week 16. Planned start Dec 2023; status: authorised.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-505120-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505120-59-00.